EDAP wins CPT code for prostate cancer ablation
French therapeutic ultrasound developer EDAP said that the American Medical...Read more on AuntMinnie.comRelated Reading: EDAP seeks clearance for ultrasound device
ConclusionsPre-biopsy mpMRI for clinically suspected prostate cancer is emerging as a standard of practice in Ireland. International guidelines are also changing to reflect latest clinical trial evidence. Private health insurance providers should amend their policies to reflect current clinical practices already adopted in the public sector.
Authors: De Luca S, Fiori C, Bollito E, Garrou D, Aimar R, Cattaneo G, De Cillis S, Manfredi M, Tota D, Massa F, Passera R, Porpiglia F Abstract BACKGROUND: To evaluate if multiparametric magnetic resonance (mpMRI)- transrectal ultrasound (TRUS) fusion targeted biopsy (TBx) versus untargeted standard biopsy (SBx) may decrease the rate of pathological upgrading of Gleason score (GS) 3+4 prostate cancer (PCa) at radical prostatectomy (RP). We also evaluated the impact of percent pattern 4 and cribriform glands at biopsy in the risk of GS 3 + 4 = 7 upgrading. METHODS: 301 patients with GS 3+4 PCa on biopsy (159 SB...
CONCLUSIONS: Focal therapy of CaP lesions with a robotic HIFU-probe is safe and renders an acceptable rate of minor early AEs. The inclusion of the urethra in the ablation zone leads to an increase in early complications and should be avoided whenever possible. PMID: 31628038 [PubMed - as supplied by publisher]
Paul Sayer, 64, from Southend-on-Sea in Essex, was diagnosed with cancer in his 60s. He had high-intensity focused ultrasound treatment in July 2018 and suffered no complications afterwards.
CONCLUSIONS: The rate of overall complications after TRUS was low. The most common complications requiring emergency attendances and hospitalisations were gross haematuria and acute urinary retention, respectively. Prostate volume>48 cc increased the risk of post-biopsy urinary retention. PMID: 31601774 [PubMed - as supplied by publisher]
Publication date: October 2019Source: European Urology Supplements, Volume 18, Issue 9Author(s): D. Maffei, M. Paciotti, M. Lazzeri, L. Zhang, N. Frego, P. Colombo, P. Casale, R. Hurle, A. Saita, N. Buffi, G. Guazzoni, G. Lughezzani
Publication date: October 2019Source: European Urology Supplements, Volume 18, Issue 9Author(s): F. Chessa, A. Ercolino, C. Gaudiano, D. Giusti, L. Bianchi, M. Borghesi, C. Pultrone, E. Marcelli, L. Lodigiani, R. Schiavina, E. Brunocilla
Publication date: October 2019Source: European Urology Supplements, Volume 18, Issue 9Author(s): G. Di Cosmo, A. Russo, L. Lopez, R. Gaston
CONCLUSIONS: Prostate biopsies may lead to a tumor-associated release of CTCs into the blood circulation. Larger confirmatory trials with longer follow-up periods are required before any change in clinical practice can be recommended. PMID: 31601564 [PubMed - as supplied by publisher]
ConclusionsIn this paper, technical feasibility of multiparametric machine learning to improve upon single US modalities for the localization of PCa has been demonstrated. Extended datasets for training and testing may establish the clinical value of automatic multiparametric US classification in the early diagnosis of PCa.Key Points• Combination of B-mode ultrasound, shear-wave elastography, and contrast ultrasound radiomics through machine learning is technically feasible.• Multiparametric ultrasound demonstrated a higher prostate cancer localization ability than single ultrasound modalities.• Computer-aid...